Surrozen, Inc./DE Payments for Restructuring
Surrozen, Inc./DE (SRZN) reported Payments for Restructuring of $44.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2025-03-31
- Surrozen, Inc./DE payments for restructuring for the quarter ending 2023-09-30 was $1.30M.
- Surrozen, Inc./DE payments for restructuring for the quarter ending 2023-06-30 was $457.00K.
- Surrozen, Inc./DE payments for restructuring for the quarter ending 2023-03-31 was $726.00K.
- Surrozen, Inc./DE payments for restructuring for fiscal 2024 was $44.00K, a 98.36% decline from fiscal 2023.
- Surrozen, Inc./DE payments for restructuring for fiscal 2023 was $2.68M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2024-12-31 | $44.00K 10-K · filed 2025-03-31 | |||
| 2023-12-31 | $2.68M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $1.30M 10-Q · filed 2024-11-06 | $1.76M derived: sum of 2 quarters · filed 2024-11-06 | $2.49M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $457.00K 10-Q · filed 2024-11-06 | $1.18M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $726.00K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |